Cargando…

Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk

The mechanisms leading to the development of heart failure (HF) in diabetes mellitus (DM) patients are multifactorial. Assessing the risk of HF development in patients with DM is valuable not only for the identification of a high-risk subgroup, but also equally important for defining low-risk subpop...

Descripción completa

Detalles Bibliográficos
Autores principales: Chrysohoou, Christina, Fragoulis, Christos, Leontsinis, Ioannis, Gastouniotis, Ioannis, Fragouli, Dimitra, Georgopoulos, Maximos, Mantzouranis, Emmanouil, Noutsou, Marina, Tsioufis, Konstantinos P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056430/
https://www.ncbi.nlm.nih.gov/pubmed/36986114
http://dx.doi.org/10.3390/nu15061384
_version_ 1785016119511220224
author Chrysohoou, Christina
Fragoulis, Christos
Leontsinis, Ioannis
Gastouniotis, Ioannis
Fragouli, Dimitra
Georgopoulos, Maximos
Mantzouranis, Emmanouil
Noutsou, Marina
Tsioufis, Konstantinos P.
author_facet Chrysohoou, Christina
Fragoulis, Christos
Leontsinis, Ioannis
Gastouniotis, Ioannis
Fragouli, Dimitra
Georgopoulos, Maximos
Mantzouranis, Emmanouil
Noutsou, Marina
Tsioufis, Konstantinos P.
author_sort Chrysohoou, Christina
collection PubMed
description The mechanisms leading to the development of heart failure (HF) in diabetes mellitus (DM) patients are multifactorial. Assessing the risk of HF development in patients with DM is valuable not only for the identification of a high-risk subgroup, but also equally important for defining low-risk subpopulations. Nowadays, DM and HF have been recognized as sharing similar metabolic pathways. Moreover, the clinical manifestation of HF can be independent of LVEF classification. Consequently, approaching HF should be through structural, hemodynamic and functional evaluation. Thus, both imaging parameters and biomarkers are important tools for the recognition of diabetic patients at risk of HF manifestation and HF phenotypes, and arrhythmogenic risk, and eventually for prognosis, aiming to improve patients’ outcomes utilizing drugs and non-pharmaceutical cardioprotective tools such as diet modification.
format Online
Article
Text
id pubmed-10056430
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100564302023-03-30 Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk Chrysohoou, Christina Fragoulis, Christos Leontsinis, Ioannis Gastouniotis, Ioannis Fragouli, Dimitra Georgopoulos, Maximos Mantzouranis, Emmanouil Noutsou, Marina Tsioufis, Konstantinos P. Nutrients Review The mechanisms leading to the development of heart failure (HF) in diabetes mellitus (DM) patients are multifactorial. Assessing the risk of HF development in patients with DM is valuable not only for the identification of a high-risk subgroup, but also equally important for defining low-risk subpopulations. Nowadays, DM and HF have been recognized as sharing similar metabolic pathways. Moreover, the clinical manifestation of HF can be independent of LVEF classification. Consequently, approaching HF should be through structural, hemodynamic and functional evaluation. Thus, both imaging parameters and biomarkers are important tools for the recognition of diabetic patients at risk of HF manifestation and HF phenotypes, and arrhythmogenic risk, and eventually for prognosis, aiming to improve patients’ outcomes utilizing drugs and non-pharmaceutical cardioprotective tools such as diet modification. MDPI 2023-03-13 /pmc/articles/PMC10056430/ /pubmed/36986114 http://dx.doi.org/10.3390/nu15061384 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chrysohoou, Christina
Fragoulis, Christos
Leontsinis, Ioannis
Gastouniotis, Ioannis
Fragouli, Dimitra
Georgopoulos, Maximos
Mantzouranis, Emmanouil
Noutsou, Marina
Tsioufis, Konstantinos P.
Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk
title Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk
title_full Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk
title_fullStr Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk
title_full_unstemmed Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk
title_short Cardiometabolic Care: Assessing Patients with Diabetes Mellitus with No Overt Cardiovascular Disease in the Light of Heart Failure Development Risk
title_sort cardiometabolic care: assessing patients with diabetes mellitus with no overt cardiovascular disease in the light of heart failure development risk
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056430/
https://www.ncbi.nlm.nih.gov/pubmed/36986114
http://dx.doi.org/10.3390/nu15061384
work_keys_str_mv AT chrysohoouchristina cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk
AT fragoulischristos cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk
AT leontsinisioannis cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk
AT gastouniotisioannis cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk
AT fragoulidimitra cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk
AT georgopoulosmaximos cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk
AT mantzouranisemmanouil cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk
AT noutsoumarina cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk
AT tsioufiskonstantinosp cardiometaboliccareassessingpatientswithdiabetesmellituswithnoovertcardiovasculardiseaseinthelightofheartfailuredevelopmentrisk